Effect of initial ziprasidone dose on length of therapy in schizophrenia

This publication has 16 references indexed in Scilit:

• Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
  New England Journal of Medicine, 2005
• Impact of Concurrent Medication Use on Statin Adherence and Refill Persistence
  Archives of internal medicine (1960), 2004
• Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia
  American Journal of Psychiatry, 2004
• Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia
  The Journal of Clinical Psychiatry, 2002
• Health Behaviors and Health Status of Older Women With Schizophrenia
  Psychiatric Services, 2002
• Ziprasidone in the Short-Term Treatment of Patients with Schizoaffective Disorder: Results from Two Double-Blind, Placebo-Controlled, Multicenter Studies
  Journal of Clinical Psychopharmacology, 2001
• Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled Trial
  Neuropsychopharmacology, 1999
• Atypical Antipsychotics: Part II Adverse Effects, Drug Interactions, and Costs
  Annals of Pharmacotherapy, 1999
• Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial
  Psychopharmacology, 1998
• The number needed to treat: a clinically useful measure of treatment effect
  BMJ, 1995